Elanco to Participate in Stifel 2024 Jaws and Paws Conference

5/21/24 8:00:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ELAN alert in real time by email

GREENFIELD, Ind. , May 21, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will participate in the Stifel 2024 Jaws and Paws Conference on Wednesday, May 29, 2024. Todd Young, executive vice president and CFO, will participate in a fireside chat at 8:00 a.m. ET.

A live audio webcast will be available in the "Events and Presentations" section of Elanco's investor website. A replay will be available for approximately 30 days.

ABOUT ELANCO

Elanco Animal Health Incorporated (NYSE:ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With nearly 70 years of animal health heritage, we are committed to helping our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our Elanco Healthy Purpose– all to advance the health of animals, people, the planet and our enterprise. Learn more at www.elanco.com.

Investor Contact: Katy Grissom (317) 273-9248 [email protected]

Media Contact: Colleen Parr Dekker (317) 989-7011 [email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/elanco-to-participate-in-stifel-2024-jaws-and-paws-conference-302150563.html

SOURCE Elanco Animal Health

Get the next $ELAN alert in real time by email

Recent Analyst Ratings for

$ELAN

Date	Price Target	Rating	Analyst
9/19/2024	$17.00 → $15.00	Overweight → Equal-Weight	Morgan Stanley
1/5/2024	$13.00 → $20.00	Hold → Buy	Stifel
12/19/2023	$17.00	Buy	Jefferies
12/15/2023	$16.00	Equal-Weight → Overweight	Morgan Stanley
12/7/2023	$18.00	Outperform	Exane BNP Paribas
4/20/2023	$14.00	Equal Weight → Overweight	Barclays
8/18/2022	$37.00 → $22.00	Overweight → Equal-Weight	Morgan Stanley
8/16/2022	$28.00 → $24.00	Overweight → Neutral	JP Morgan

More analyst ratings

Elanco to Participate in Stifel 2024 Jaws and Paws Conference

Chat with this insight

Recent Analyst Ratings for $ELAN

$ELAN Financials

Live finance-specific insights

Elanco Confirms Date and Conference Call for Third Quarter 2024 Financial Results Announcement

Elanco Announces FDA Approval and Launch of Zenrelia™ (ilunocitinib tablets), Offering An Effective, Safe Solution in Canine Dermatology

Elanco Confirms Date and Conference Call for Second Quarter 2024 Financial Results Announcement

$ELAN Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Elanco Animal Health Incorporated

SEC Form SC 13G/A filed by Elanco Animal Health Incorporated (Amendment)

SEC Form SC 13G/A filed by Elanco Animal Health Incorporated (Amendment)

$ELAN Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by PRESIDENT, CEO AND DIRECTOR Simmons Jeffrey N

SEC Form 4 filed by Officer Modi Rajeev A.

SEC Form 4 filed by PRESIDENT, CEO AND DIRECTOR Simmons Jeffrey N

$ELAN Market Insights

Live Market Insights

Merk Animal Health Completes Acquisition of Elanco Animal Health Assets

Citigroup, Elanco Animal Health And A Tech Stock: CNBC's 'Final Trades'

Corning, Elanco, Citigroup: CNBC's 'Final Trades'

$ELAN Leadership Updates

Live Leadership Updates

$ELAN Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

$ELAN Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

$ELAN SEC Filings

Elanco Appoints Two Animal Health Industry Executives, Kathy Turner and Craig Wallace, to its Board of Directors

Elanco Appoints Shiv O'Neill as General Counsel and Corporate Secretary

Elanco Launches Multi-Year Mission to Save 1 Million Puppies from Canine Parvovirus

Director Harrington Michael J bought $51,974 worth of shares (3,500 units at $14.85), increasing direct ownership by 5% to 81,094 units (SEC Form 4)

PRESIDENT, CEO AND DIRECTOR Simmons Jeffrey N bought $1,300,610 worth of shares (100,000 units at $13.01) (SEC Form 4)

Doyle William F bought $254,700 worth of shares (15,000 units at $16.98), increasing direct ownership by 24% to 76,330 units (SEC Form 4)

Elanco Animal Health downgraded by Morgan Stanley with a new price target

Elanco Animal Health upgraded by Stifel with a new price target

Jefferies initiated coverage on Elanco Animal Health with a new price target

Elanco Animal Health Incorporated filed SEC Form 8-K: Regulation FD Disclosure

Elanco Animal Health Incorporated filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

SEC Form 10-Q filed by Elanco Animal Health Incorporated

$ELAN Press Releases

Fastest customizable press release news feed in the world

Elanco Confirms Date and Conference Call for Third Quarter 2024 Financial Results Announcement

Elanco Receives FDA Approval for Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets), the Broadest(i) Canine Oral Parasiticide Protection in a Single Monthly Dose

Elanco Announces FDA Approval and Launch of Zenrelia™ (ilunocitinib tablets), Offering An Effective, Safe Solution in Canine Dermatology

Recent Analyst Ratings for
$ELAN

$ELAN
Financials

$ELAN
Large Ownership Changes

$ELAN
Insider Trading

$ELAN
Market Insights

$ELAN
Leadership Updates

$ELAN
Insider Purchases

$ELAN
Analyst Ratings

$ELAN
SEC Filings

$ELAN
Press Releases